CXCL10 and lobular neoplasia: IP-10 has been investigated as a possible serum or urine biomarker for LN in SLE patients, but results pertaining to IP-10 as a biomarker for activity or disease progression/remission are inconsistent, and biologic levels in other forms of glomerular diseases (GD) are unknown.